Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1333493-13-2

Post Buying Request

1333493-13-2 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1333493-13-2 Usage

General Description

The chemical (R)-4-(7-Ethyl-8-isopropyl-5-Methyl-6-oxo-5,6,7,8-tetrahydro-pteridin-2-ylamino)-3-methoxy-benzoic acid is a compound containing a pteridine ring structure and a benzoic acid moiety. It is classified as an amino acid derivative and is commonly used in pharmaceutical research and development. This chemical has potential applications in the field of medicine, particularly in the development of new drugs for the treatment of various conditions. Its precise biological activity and therapeutic potential are the subjects of ongoing research and investigation.

Check Digit Verification of cas no

The CAS Registry Mumber 1333493-13-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,3,3,4,9 and 3 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1333493-13:
(9*1)+(8*3)+(7*3)+(6*3)+(5*4)+(4*9)+(3*3)+(2*1)+(1*3)=142
142 % 10 = 2
So 1333493-13-2 is a valid CAS Registry Number.

1333493-13-2Downstream Products

1333493-13-2Relevant articles and documents

Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors

Liu, Shuai,Yosief, Hailemichael O.,Dai, Lingling,Huang, He,Dhawan, Gagan,Zhang, Xiaofeng,Muthengi, Alex M.,Roberts, Justin,Buckley, Dennis L.,Perry, Jennifer A.,Wu, Lei,Bradner, James E.,Qi, Jun,Zhang, Wei

, p. 7785 - 7795 (2018/09/13)

The simultaneous inhibition of polo-like kinase 1 (PLK1) and BRD4 bromodomain by a single molecule could lead to the development of an effective therapeutic strategy for a variety of diseases in which PLK1 and BRD4 are implicated. Compound 23 has been found to be a potent dual kinase-bromodomain inhibitor (BRD4-BD1 IC50 = 28 nM, PLK1 IC50 = 40 nM). Compound 6 was found to be the most selective PLK1 inhibitor over BRD4 in our series (BRD4-BD1 IC50 = 2579 nM, PLK1 IC50 = 9.9 nM). Molecular docking studies with 23 and BRD4-BD1/PLK1 as well as with 6 corroborate the biochemical assay results.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1333493-13-2